Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered ADC in Solid Tumors
核心洞察
Natera and Angiex have announced a collaboration to use Signatera ctDNA testing for longitudinal response monitoring in Angiex's Phase 1 trial of AGX101.
AGX101 is a TM4SF1 (搜索)-directed Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) targeting both tumor cells and tumor-associated endothelial cells in advanced solid tumors (搜索).
Signatera's personalized ctDNA monitoring may complement imaging by offering additional insights when radiological findings are uncertain.
Natera, Inc. (NTRA), a company specializing in cell-free DNA and precision medicine, has announced a collaboration with Angiex, Inc., a privately held biotechnology company developing Nuclear-Delivered Antibody-Drug Conjugates (ND-ADCs). Under the agreement, Natera's Signatera test will be used for longitudinal circulating tumor DNA (ctDNA) monitoring to assess treatment response in Angiex's ongoing Phase 1 clinical trial of AGX101.
AGX101 is an investigational therapy designed to target TM4SF1 (搜索)-expressing tumor cells and tumor-associated endothelial cells. This dual-targeting approach aims to address both tumor cells and the supporting vasculature in patients with unresectable, locally advanced or metastatic solid tumors (搜索). The AGX101 clinical trial is identified as NCT06440005.
Based in Cambridge, Mass., Angiex was founded by leading experts in angiogenesis, vascular biology, and oncology. The company's lead candidate, AGX101, builds on 22 years of biology research and 14 years of drug development.
A Dual-Targeting Approach to Solid Tumors
Angiex's Nuclear-Delivered Antibody-Drug Conjugates represent a differentiated therapeutic strategy. AGX101 is a TM4SF1 (搜索)-directed ADC currently in Phase 1 clinical trials for solid tumors (搜索). By targeting both TM4SF1-expressing tumor cells and tumor-associated endothelial cells, the therapy is designed to address the tumor itself as well as its supporting vasculature.
Paul Jaminet, Ph.D., co-founder and CEO of Angiex, stated that AGX101 has the potential to deliver a differentiated therapeutic approach for patients with advanced solid tumors (搜索), and that ctDNA monitoring could enhance understanding of treatment response.
The Role of Signatera in Response Monitoring
Signatera provides a personalized measure of ctDNA that may complement imaging, offering additional insights when radiological findings are uncertain. Eric Matthews, general manager of biopharma at Natera, added that Signatera provides depth into early biologic response assessment, which may inform AGX101's development and advance this novel drug class.
Natera operates CLIA-certified laboratories in Texas, California, and Colorado, with its tests supported by more than 400 peer-reviewed publications.
Advancing Precision Diagnostics in Oncology
This partnership underscores the growing role of precision diagnostics in oncology and highlights the potential of ctDNA testing to complement traditional imaging in clinical trials. By integrating longitudinal ctDNA monitoring into the Phase 1 evaluation of AGX101, the collaboration aims to enhance understanding of treatment response and support the development of the ND-ADC drug class.